TMFBiologyFool

Brian Orelli

Somewhere between his graduate thesis on BRCA1, a gene that causes hereditary breast cancer, and his postdoctoral fellowship in DNA repair, Brian realized he enjoyed analyzing other people's data more than running his own experiments. Having gotten his first taste of how to analyze stocks from The Motley Fool many years prior, it was only fitting that he came full circle and started writing about biotech, pharmaceutical, and medical device companies for Fool.com. He also covers the health insurance industry to keep from going into binary-event overload. When not writing at The Motley Fool or trade journals like Nature Biotechnology and BioWorld, Brian can be found coaching soccer or hanging out at the beach in his hometown of San Diego.

TMFBiologyFool’s Activity

Yesterday

Rule Breakers article.

TMFBiologyFool published an update. 12:54 PM

Thu Oct 30

NL

Article

TMFBiologyFool published an article 7:22 PM

Seattle Genetics, Inc. Posts Record Adcetris Sales

A solid quarter for the biotech allowed it to raise guidance for the year.

Wed Oct 29

Rule Breakers article.

TMFBiologyFool published an update. 10:00 AM

Tue Oct 28

NL

Article

TMFBiologyFool published an article 7:41 PM

Vertex Pharmaceuticals Incorporated Plays the Earnings Waiting Game

Year-over-year growth of 25% is impressive but pales in comparison with Vertex's potential.

Sat Oct 25

Stock Advisor article.

TMFBiologyFool published an update. 2:24 PM

Rule Breakers article.

TMFBiologyFool published an update. 2:08 PM

Fri Oct 24

NL

Article

TMFBiologyFool published an article 5:41 PM

IDEXX Laboratories, Inc. Is as Fit as a Butcher's Dog

A strong third quarter helped the animal testing company raise 2014 guidance.

NL

Article

TMFBiologyFool published an article 11:52 AM

ImmunoGen, Inc. Pushes Forward

With just $4.2 million in royalties from Roche's Kadcyla, investors need to be focused on ImmunoGen's internal pipeline.

Rule Breakers article.

TMFBiologyFool published an update. 11:15 AM

Thu Oct 23

Rule Breakers article.

TMFBiologyFool published an update. 9:59 PM

NL

Article

TMFBiologyFool published an article 7:17 PM

BioMarin Pharmaceutical Inc. Earnings: Striving to Be a Blockbuster Company

A solid third quarter puts BioMarin on target for more than $700 million in revenue this year, within striking distance of $1 billion in annual revenue.

NL

Article

TMFBiologyFool published an article 12:15 PM

Revlimid: Celgene Corporation's Gift That Keeps on Giving

Nearly nine years after FDA approval, Revlimid is still growing at 19%; other Celgene drugs aren't as prolific.

Wed Oct 22

Hidden Gems article.

TMFBiologyFool published an update. 4:36 PM

NL

Article

TMFBiologyFool published an article 3:24 PM

Biogen Idec inc Earnings Were Great. Here's Why the Stock Tumbled Anyway

Instead of Tysabri, it's Tecfidera this time.

NL

Article

TMFBiologyFool published an article 1:12 PM

Natus Medical Inc. Hears Higher Margins Calling

Revenue growth was only 5% but improving margins helped increase non-GAAP net income by 16.5%.

Rule Breakers article.

TMFBiologyFool published an update. 11:31 AM

Rule Breakers article.

TMFBiologyFool published an update. 10:00 AM

Tue Oct 21

NL

Article

TMFBiologyFool published an article 8:12 PM

Intuitive Surgical Inc.'s Margins Go Under the Knife

Gross margin slips 200 basis points quarter over quarter, though mostly from temporary issues.

NL

Article

TMFBiologyFool published an article 3:45 PM

Celgene Corporation's Earnings Preview: Pay Attention to New Kids

Revlimid might be the flagship, but growth will come from the newer drugs.

Mon Oct 20

NL

Article

TMFBiologyFool published an article 7:08 PM

How Gilead Sciences Inc. Isn't Gouging Hepatitis C Patients, in 1 Simple Infographic

Gilead Sciences' Harvoni is actually cheaper than other treatments.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating 95.34
Player Rank 3496 out of 75062
Score 1139.47
Score Change Today -50.23
Accuracy 65.87%
Active Picks 73
Total Picks 213
Best Pick MYL (+290.49)
Worst Pick INCY (-588.29)
Average Score per Pick 5.35
Charms Earned 9
Highest Rated Favorite zzlangerhans
Go to TMFBiologyFool’s CAPS page

Boards Stats & Trivia

Three stars, 500 posts CAPS All Star
Board Posts 928
Recs Received 982
People who have rec'd these posts 380
Recs to Posts Ratio (last 30 days) N/A
Threads Started 90
Threads Started Percentage 9.70 %
Most Frequent Board Buying or Selling a Home
Very First Post Re: How many is enough? (6/6/2001)
Percentage of Posts Rec'd 48.17 %
Show TMFBiologyFool’s 10 Latest Posts